Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand.

Kulpeng, Wantanee

Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand. [electronic resource] - Clinical therapeutics Apr 2014 - 534-43 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1879-114X

10.1016/j.clinthera.2014.02.008 doi


Budgets
Cost-Benefit Analysis
Dasatinib--economics
Drug Costs
Humans
Imatinib Mesylate--economics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Leukemia, Myeloid, Chronic-Phase--drug therapy
Markov Chains
Protein Kinase Inhibitors--economics
Pyrimidines--economics
Quality of Life
Quality-Adjusted Life Years
Thailand